Summary
Spectral Medical Inc., together with its subsidiaries, focuses on the development and commercialization of products for the treatment of septic shock and renal disease in North America. The company markets Endotoxin Activity Assay, a rapid in vitro diagnostic test for the detection of components of gram negative bacterial cell wall; and Polymyxin B Hemoperfusion, a therapeutic hemoperfusion device that removes endotoxin from the bloodstream. It also develops and manufactures monoclonal and polyclonal antibodies, recombinant cardiac proteins, and calibrators for use in the research and development, as well as products that are manufactured by other diagnostic companies; and develops platform for renal replacement therapy. The company was formerly known as Spectral Diagnostics Inc. and changed its name to Spectral Medical Inc. in December 2014. Spectral Medical Inc. was incorporated in 1991 and is headquartered in Toronto, Canada.
History
Founded in 2009, Spectral Medical has quickly become a leader in developing highly effective treatments for sepsis and related conditions. The company's groundbreaking immune-targeted therapies, Oridion and Fidentia, have received industry recognition and multiple awards.
Mission
Our mission is to improve the health and quality of life of patients suffering from sepsis and related conditions with the use of innovative diagnostics, therapies and related products.
Vision
Our vision is to be the leading provider of effective treatments for sepsis and related conditions, enabling clinicians to diagnose and treat sepsis quickly and accurately.
Key Team
Mr. Blair McInnis (Chief Financial Officer)
Mr. Sam Amory (Pres of Dialco Medical Inc.)
Recognition and Awards
Spectral Medical has been recognized for its groundbreaking therapeutic approach. The company has won two international awards for its therapies as well as numerous other accolades from key healthcare and scientific institutions around the world.
References
